Christopher A. Zimmer

Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure

Lisa C. Costello‐Boerrigter, William B. Smith, Guido Boerrigter et al. · American Journal of Physiology-Renal Physiology · 2005 · 259 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

Paul B. Watkins, James H. Lewis, Neil Kaplowitz et al. · Drug Safety · 2015 · 192 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction

James E. Udelson, Cesare Orlandi, John Ouyang et al. · Journal of the American College of Cardiology · 2008 · 180 citations

Medicine, Cardiology, Pharmacology +17

Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan, a Non-Peptide AVP Antagonist, and Furosemide or Hydrochlorothiazide

Susan E. Shoaf, Steven L. Bramer, Patricia Bricmont et al. · Journal of Cardiovascular Pharmacology · 2007 · 58 citations

Medicine, Pharmacokinetics, Pharmacology +12

Influence of knot configuration and tying technique on the mechanical performance of sutures

Christopher A. Zimmer, John G. Thacker, David M. Powell et al. · Journal of Emergency Medicine · 1991 · 55 citations

Natural Sciences, Surgery, Mechanical Behavior Of Materials +7